Responsiveness of clinical outcome measures in Charcot−Marie−Tooth disease-Reference-Cited by-同舟云学术

Responsiveness of clinical outcome measures in Charcot−Marie−Tooth disease

Published:2015-07-31 Issue:12 Volume:22 Page:1556-1563
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Piscosquito G.¹,Reilly M. M.²,Schenone A.³,Fabrizi G. M.⁴,Cavallaro T.⁴,Santoro L.⁵,Manganelli F.⁵,Vita G.⁶⁷,Quattrone A.⁸,Padua L.⁹,Gemignani F.¹⁰,Visioli F.¹¹¹²,Laurà M.²,Calabrese D.¹,Hughes R. A. C.²,Radice D.¹³,Solari A.¹,Pareyson D.¹,

Affiliation:

1. C. Besta Neurological Institute; IRCCS Foundation; Milan Italy

2. MRC Centre for Neuromuscular Diseases; Institute of Neurology; University College London; London UK

3. Department of Neurology, Ophthalmology and Genetics; University of Genoa; Genoa Italy

4. Department of Neurological, Neuropsychological, Morphological and Motor Sciences; University of Verona; Verona Italy

5. Department of Neurosciences, Reproductive and Odontostomatological Sciences; University Federico II of Naples; Naples Italy

6. Department of Neurosciences; University of Messina; Messina Italy

7. Clinical Centre NEMO SUD; Fondazione Aurora Onlus; Messina Italy

8. Neurology Clinic; Neuroimaging Research Unit; National Research Council; Magna Graecia University; Catanzaro Italy

9. Department of Geriatrics; Neurosciences and Orthopaedics - Università Cattolica del Sacro Cuore; Rome; Don Carlo Gnocchi Foundation Milan Italy

10. Department of Neurosciences; University of Parma; Parma Italy

11. Department of Pharmacological Sciences; University School of Pharmacy; Milan Italy

12. Department of Molecular Medicine; University of Padua; Padua Italy

13. Department of Epidemiology and Biostatistics; European Institute of Oncology; Milan Italy

Funder

Telethon-UILDM

Agenzia Italiana del Farmaco, Ministero della Salute

Muscular Dystrophy Campaign in the UK

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.12783/fullpdf

Reference36 articles.

1. Ascorbic acid for Charcot−Marie−Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial;Burns;Lancet Neurol,2009

2. Effect of ascorbic acid in patients with Charcot−Marie−Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial;Micallef;Lancet Neurol,2009

3. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial;Verhamme;BMC Med,2009

4. Ascorbic acid in Charcot−Marie−Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. CMT-TRIAAL; CMT-TRAUK groups;Pareyson;Lancet Neurol,2011

5. Reliability and validity of the CMT neuropathy score as a measure of disability;Shy;Neurology,2005

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure;Neurology;2024-02-13

2. Quantitative MRI outcome measures in CMT1A using automated lower limb muscle segmentation;Journal of Neurology, Neurosurgery & Psychiatry;2023-11-18

3. Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease;Neuromuscular Disorders;2023-08

4. Disease‐specific wearable sensor algorithms for profiling activity, gait, and balance in individuals with Charcot–Marie–Tooth disease type 1A;Journal of the Peripheral Nervous System;2023-06-13

5. Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints;Annals of Neurology;2023-03-21